Nina Kjellson is a General Partner at Canaan Partners, an early-stage venture capital firm, where she invests in biopharmaceutical start-ups across modalities in high unmet need areas. She is a director of Tyra Biosciences (NADSAQ: TYRA), and of Actio Biosciences, Rondo Therapeutics, Sardona, Tizona, and Trishula, as well as Proxygen, a non-Canaan company based in Austria. Prior to Canaan, Nina was a General Partner at InterWest Partners where she backed many life science companies including Aspreva (ASPV; acqd by Galenica); Cidara (CDTX); CNS Therapeutics (acqd by Mallinckrodt), Eiger (EIGR), Labrys(acqd by Teva) Novacardia (acqd by Merck), Paratek (PRTK), Tesaro (TSRX, acqd by GSK) and Trius (TRSX, acqd by Cubist). Prior to InterWest, Nina worked at Bay City Capital and Oracle Partners. She began her career supporting health policy research, polling and journalism at the Kaiser Family Foundation. As a founder of WoVen: Women Who Venture, Nina is a vocal advocate for women entrepreneurs and investors. She is a Health Innovators Fellow of the Aspen Institute and serves as a director of BIO.org, the Foundation for the National Institutes of Health (FNIH), Life Sciences Cares (co-chairing the Bay Area affiliate) and Girl Effect. She advises Oliver Wyman as part of their Health Care Leadership Council and is an advisor to SPARK Neuroscience. Nina holds a B.A. in human biology with emphasis on health policy and bioethics from Stanford University. She was born in Finland and keeps close ties to her European roots. She is an avid hiker and skier and loves to travel and to gather with friends and family.